Neupogen 30mu/0.5ml 1 Prefilled Syringe (Refrigerated)

Active Ingredient: Filgrastim Myelosuppressive chemotherapy recipients with nonmyeloid malignancies: Neupogen (filgrastim), Zarxio (filgrastim-sndz [biosimilar]), Grastofil [Canadian product]: To decrease the incidence of infection (neutropenic fever) in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a significant incidence of severe neutropenia with fever. Granix (tbo-filgrastim): To decrease the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of neutropenic fever. Acute myeloid leukemia (AML) following induction or consolidation chemotherapy (Neupogen, Zarxio, Grastofil [Canadian product]): To reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy in adults with AML. Bone marrow transplantation (Neupogen, Zarxio, Grastofil [Canadian product]): To reduce the duration of neutropenia and neutropenia-related events (eg, neutropenic fever) in patients with nonmyeloid malignancies receiving myeloablative chemotherapy followed by marrow transplantation. Hematopoietic radiation injury syndrome, acute (Neupogen): To increase survival in patients acutely exposed to myelosuppressive doses of radiation. Peripheral blood progenitor cell collection and therapy (Neupogen, Zarxio, Grastofil [Canadian product]): Mobilization of autologous hematopoietic progenitor cells into the peripheral blood for apheresis collection. Severe chronic neutropenia (Neupogen, Zarxio, Grastofil [Canadian product]): Long-term administration to reduce the incidence and duration of neutropenic complications (eg, fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital, cyclic, or idiopathic neutropenia.